Sustabol 350
Overview
Sustabol 350 British Dragon is a four-ester testosterone blend formulated at 350 mg/ml — a higher concentration than the standard 250 mg/ml Sustanon formulation — supplied in a 10 ml vial containing 3,500 mg of testosterone in total. The multi-ester profile combines a fast-acting propionate fraction for rapid onset with medium and long-acting phenylpropionate, isocaproate, and decanoate fractions that sustain serum testosterone throughout the injection interval. The result is a blend suited to cycles of 10–16 weeks where a single compound covers both the initial testosterone elevation and its maintenance over the full cycle duration. The complete British Dragon testosterone range is available at steroidwarehouse.com alongside Sustabol 350.
About the Compound
Sustabol 350 follows the classic four-ester testosterone blend model: the propionate fraction provides a serum testosterone peak within the first 24–48 hours of injection; phenylpropionate and isocaproate extend that peak through the mid-interval; and decanoate maintains trough levels between injections, preventing the steep drops that can occur with single short-ester testosterone products. At 350 mg/ml, the concentration is 40% higher than standard Sustanon blends, meaning a full 350 mg dose requires only 1 ml of injection volume — a practical advantage over lower-concentration formulations when weekly doses exceed 500 mg.
Testosterone aromatizes to estradiol (E2) via aromatase, making estrogen management mandatory for most users above 350 mg/week. Without AI support, rising E2 causes water retention, increased blood pressure, and gynecomastia risk. Testosterone also suppresses the HPG axis completely within 1–2 weeks of cycle start, requiring full post-cycle therapy after the ester load has cleared.
What It Does
- Rapid testosterone onset: The propionate fraction raises serum testosterone within 24–48 hours of the first injection, avoiding the 2–3 week delay associated with single long-ester testosterone products. Users typically notice elevated drive, recovery, and training output within the first week.
- Sustained serum levels between injections: The decanoate fraction maintains trough testosterone levels, reducing the amplitude of peak-to-trough variation across the injection interval. This translates to more consistent anabolic signaling and fewer mood or energy fluctuations between injections compared to short-ester-only protocols.
- Lean mass and nitrogen retention: Testosterone drives positive nitrogen balance and increases protein synthesis in muscle tissue. At doses of 350–700 mg/week, lean mass accrual is consistent and measurable within 4–6 weeks, with quality of gains depending heavily on dietary protein intake and caloric environment.
- Red blood cell production: Testosterone stimulates erythropoietin production, increasing red blood cell count and hemoglobin. This contributes to improved oxygen delivery to muscle tissue and enhanced endurance capacity during training, while also requiring hematocrit monitoring to prevent polycythemia.
- IGF-1 elevation and recovery support: Testosterone upregulates hepatic IGF-1 production and enhances satellite cell activity in muscle. Combined, these effects improve recovery between sessions and support lean tissue repair during high-volume training blocks.
- SHBG suppression: Supraphysiological testosterone reduces SHBG, increasing free testosterone availability beyond what total testosterone alone would suggest. This amplifies the anabolic signal even without additional compounds in the stack.
Who It's For
Sustabol 350 is suited to intermediate and experienced users running 10–16 week testosterone-based cycles where a single compound covers the full range from onset to maintenance. The key differentiator from single-ester testosterone products is the combined pharmacokinetic profile: users get the fast onset of propionate without committing to EOD injection frequency, while the decanoate fraction prevents the trough drop that occurs between weekly injections of shorter esters.
Compared to Testabol Enanthate BD, Sustabol 350 provides faster initial testosterone elevation due to the propionate fraction, but the E2 management is slightly more complex because the blend's mixed peak profile can produce less predictable estrogen curves during the first two weeks. Users who prioritize E2 dial-in precision on a first testosterone cycle are better served by a single-ester product. Sustabol 350 is the preferred format for users familiar with multi-ester testosterone blends who want the combined convenience of a single weekly or twice-weekly injection protocol.
Users who should choose an alternative: beginners who need simple E2 titration; users planning short 8-week cycles where decanoate ester clearance would delay PCT start by 2–3 weeks; users who prefer EOD injection schedules and full control over ester clearance should use Testabol Propionate BD instead.
Sustabol 350 vs Alternatives
| Compound | Key Differences | Choose Sustabol 350 When | Choose Alternative When |
|---|---|---|---|
| Testabol Enanthate BD (Testosterone enanthate) | Single long ester; flat, predictable serum curve; onset at week 2–3; E3.5D or once-weekly injection; easier E2 titration; standard first-cycle choice | Multi-ester blend preferred; faster onset within first week; established familiarity with Sustanon-style profiles | First testosterone cycle; E2 dial-in is the priority; simple single-ester pharmacokinetics preferred |
| Testabol Depot BD (Testosterone cypionate) | Single long ester; similar half-life to enanthate (~8 days); once or twice weekly; flat serum curve; very stable blood levels; E2 management is straightforward | Mixed fast-onset plus sustained profile required; Sustanon-style blend experience; 350 mg/ml concentration preferred | Maximum blood-level stability required; once-weekly injection preferred; beginners or TRT-style protocols |
| Testabol Propionate BD (Testosterone propionate) | Single short ester; EOD injection; fast clearance; PCT within 3–4 days of last injection; more precise hormonal control; more injection events per week | Longer cycle with single weekly or E3.5D injection frequency; combined fast and sustained release in one product | Short 8-week cycle; early PCT desired; fine-tuned hormonal control via short ester; EOD injection is manageable |
Combinations
| Goal | Primary | Support Compounds | Notes |
|---|---|---|---|
| Lean mass / clean bulk | Sustabol 350 BD 350 mg/wk | Anastrozole BD | Conservative testosterone base at 350 mg/week; Anastrozole at 0.5 mg EOD manages aromatization; first-use multi-ester cycle; reliable lean mass protocol with controlled estrogen |
| Strength + mass | Sustabol 350 BD 500–700 mg/wk | Anastrozole BD + Stanabol 50 Inj BD (final 8 weeks) | Higher-dose testosterone base for mass and strength; Anastrozole manages E2 at elevated doses; Stanabol 50 Inj added in the final 8 weeks for SHBG reduction, vascularity, and hardness heading into cycle end |
| Pre-contest / recomposition | Sustabol 350 BD 350 mg/wk | Mastabol 100 BD + Anastrozole BD | Sustabol provides testosterone base; Masteron adds natural androgen:estrogen balance and muscle density; Anastrozole as E2 insurance; lean, hard pre-contest combination without excess water retention |
| Advanced mass cycle (≥12 weeks) | Sustabol 350 BD 700 mg/wk | Anastrozole BD + HCG 5000IU Dragon Pharma (on-cycle) | High-dose 12–16 week mass cycle; HCG 250 IU twice weekly on-cycle maintains testicular function and HPG responsiveness, making PCT recovery more reliable; Anastrozole mandatory at this testosterone dose |
Side Effects & Management
| Side Effect | Frequency | How to Handle It |
|---|---|---|
| Estrogenic effects (water retention, gynecomastia, elevated E2) | Very common at doses ≥350 mg/wk without AI | Start Anastrozole BD at 0.5 mg every other day from week 2–3; titrate based on E2 bloodwork at week 4; target E2 30–40 pg/mL on cycle; do not over-suppress E2 — low E2 impairs libido, joints, and mood; Tamoxifen BD for acute gynecomastia breast tissue management |
| Blood pressure elevation | Common — driven by water retention and hematocrit increase | E2 control is the primary lever; Ecosprin 75 mg/day as cardiovascular support; if BP exceeds 140/90 despite E2 control: Amlip (amlodipine) 5 mg/day as second-line; monitor weekly during the first month |
| Elevated hematocrit / erythrocytosis | Common — testosterone stimulates EPO production | Monitor hematocrit at baseline and mid-cycle; target <52%; if elevated: reduce dose, increase hydration, donate blood if eligible; Ecosprin 75 mg/day as antiplatelet support throughout |
| Androgenic effects (acne, hair loss) | Moderate to common — dose-dependent; DHT conversion via 5α-reductase | Acne: Doxycycline 100 mg/day for persistent inflammatory acne; hair loss: Finasteride DP 1 mg/day reduces DHT conversion; Minoxidil DP topical for follicle support in predisposed users |
| Lipid dysregulation (HDL suppression) | Moderate — less severe than 17α-AA oral compounds but present | Baseline lipid panel; retest every 8 weeks; post-cycle statin if HDL does not recover within 6 weeks: Rosulip or Atorlip; diet high in omega-3 throughout cycle |
| HPTA suppression | Certain — LH and FSH fully suppressed within 1–2 weeks of cycle start | Expected during any testosterone cycle; for runs ≥12 weeks: HCG 250 IU twice weekly on-cycle preserves testicular sensitivity; run full PCT after ester clearance (see PCT section) |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Estradiol (E2) | Baseline; week 4; every 6–8 weeks on cycle | 30–40 pg/mL on cycle; <20 pg/mL indicates AI over-suppression — reduce Anastrozole dose; >60 pg/mL with symptoms indicates under-management — increase AI or reduce testosterone dose |
| Hematocrit / CBC | Baseline; mid-cycle (week 6–8); end of cycle | Hematocrit <52%; values above threshold increase thrombotic risk; CBC confirms hemoglobin and platelet changes alongside hematocrit |
| LH + FSH | Baseline; 4 weeks post-PCT | Within normal range post-PCT; confirms HPG axis recovery; suppressed to near-zero on cycle — expected |
| Total testosterone | Baseline; mid-cycle; 4–8 weeks post-PCT | Recovery to pre-cycle baseline post-PCT; supraphysiological on cycle — expected; post-PCT value confirms endogenous production restored |
| HDL / LDL cholesterol | Baseline; every 8 weeks on cycle; post-PCT | HDL >40 mg/dL; LDL <130 mg/dL; testosterone suppresses HDL less aggressively than oral 17α-AA compounds but requires monitoring at higher doses |
| Blood pressure | Weekly (first month); monthly thereafter | <130/80 mmHg; E2-driven water retention is the primary driver of BP elevation on testosterone; address E2 first before reaching for antihypertensives |
| PSA (Prostate-Specific Antigen) | Baseline for users 40+; end of cycle | Within age-appropriate reference range; supraphysiological testosterone increases androgenic stimulation of prostate tissue; flag significant elevation for medical review |
PCT
Sustabol 350 contains testosterone decanoate as its longest-acting ester, with a half-life of approximately 14–15 days. This requires a clearance window of 2–3 weeks after the final injection before PCT begins — starting PCT too early, while significant ester levels remain, renders SERM therapy ineffective and extends the suppression period unnecessarily.
For cycles of 10–12 weeks: begin PCT 14–21 days after last injection. Standard protocol: Clomiphene BD 50 mg/day for weeks 1–2, then 25 mg/day for weeks 3–4; with Tamoxifen BD 20 mg/day throughout all 4 weeks.
For cycles of 12 weeks or longer: add HCG 5000IU Dragon Pharma on-cycle at 250 IU twice weekly to maintain testicular volume and HPG responsiveness during the extended suppression period. Alternatively, run a 2,500 IU HCG blast in the 10 days before PCT start. Confirm LH/FSH and total testosterone recovery via bloodwork at 4–6 weeks post-PCT completion.
Practical Summary
- Injection schedule — E3.5D (twice weekly): despite the long decanoate fraction, splitting the weekly dose into two injections every 3.5 days reduces peak-to-trough amplitude and provides more stable E2 levels than once-weekly dosing.
- Vial math: at 350 mg/week (1 ml/week) one vial covers 10 weeks; at 700 mg/week (2 ml/week) one vial covers 5 weeks; plan vial count before cycle start.
- AI from week 2–3 — do not skip: Anastrozole BD 0.5 mg EOD; titrate at week 4 based on E2 bloodwork; target 30–40 pg/mL — over-suppression causes joint pain, low libido, and mood issues.
- On-cycle HCG for runs ≥12 weeks: HCG 5000IU DP at 250 IU twice weekly maintains testicular function and makes PCT recovery significantly more reliable after extended suppression.
- PCT timing — wait for decanoate clearance: begin Clomiphene BD + Tamoxifen BD 2–3 weeks after the final injection; do not start while decanoate ester is still active.
- Hematocrit and E2 are the two non-negotiable monitoring markers: test both at baseline, week 4, and mid-cycle; Ecosprin 75 mg/day throughout as cardiovascular and antiplatelet support.
Sustabol 350 British Dragon offers the practical advantages of a four-ester testosterone blend at 350 mg/ml — a higher concentration than standard Sustanon formulations, reducing the injection volume required at any given weekly dose. The multi-ester profile suits experienced users who want rapid testosterone onset in the first days of the cycle, sustained by the longer-acting decanoate fraction throughout. It is the testosterone base of choice for cycles of 10 weeks or longer where a single compound covers the full range of goals from onset to maintenance. For athletes sourcing their cycle from Steroid Warehouse, Sustabol 350 represents a reliable and high-concentration option within the British Dragon testosterone lineup.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial evaluating 600 mg/week testosterone enanthate in healthy men with and without resistance training; demonstrated significant increases in fat-free mass, muscle size, and strength, establishing the anabolic effects of supraphysiologic testosterone administration | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on synthetic testosterone-derived anabolic-androgenic steroids, androgen receptor activity, oral and injectable forms, adverse effect profiles, misuse patterns, and monitoring considerations | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — comprehensive overview of testosterone, dihydrotestosterone, androgen receptor signaling, HPG-axis regulation, synthetic androgen pharmacology, aromatization, and endocrine suppression associated with exogenous androgen use | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| American Journal of Physiology-Endocrinology and Metabolism / PubMed | Bhasin S et al. 2001 — graded testosterone enanthate dose-response study using 25–600 mg/week for 20 weeks under GnRH suppression; demonstrated dose-dependent changes in fat-free mass, muscle size, strength, fat mass, hemoglobin concentration, HDL cholesterol, and circulating IGF-I levels | Bhasin S, et al. (2001) ↗ |
| New England Journal of Medicine / PubMed | Finkelstein JS et al. 2013 — randomized study separating testosterone and estradiol effects in men; demonstrated that estrogen deficiency primarily contributed to increased body-fat accumulation, while both testosterone and estradiol influenced sexual function and body-composition outcomes | Finkelstein JS, et al. (2013) ↗ |
What is Sustabol 350?
Sustabol 350 is an injectable testosterone blend for muscle growth; see What is Sustabol 350. It's potent—consult professionals for safe use.
What does Sustabol 350 do?
It promotes muscle mass, strength, and performance; see What Does Sustabol 350 Do. It enhances physique—monitor with labs.
Is Sustabol 350 safe?
It can be safe with responsible use and monitoring, but risks include estrogenic and cardiovascular effects; see Is Sustabol 350 Safe. Consult professionals for oversight.
How do I take Sustabol 350?
350-700 mg/week, split weekly or bi-weekly; see How to Take Sustabol 350. Start low—consult professionals for dosing.
How does Sustabol 350 work?
Sustabol 350 works by combining several testosterone esters that release at different rates, helping maintain testosterone levels while providing both immediate and long-lasting effects.
How long does it take to notice effects from Sustabol 350?
Users often report early improvements in workout performance, recovery, muscle fullness, and overall well-being, with more noticeable changes in strength and physique developing over several weeks.
What are the main benefits of Sustabol 350?
Commonly reported benefits include increased muscle mass, enhanced strength, improved recovery, greater workout performance, and support for lean muscle development.
What are the possible side effects of Sustabol 350?
Potential side effects may include water retention, acne, oily skin, estrogen-related effects, elevated blood pressure, and suppression of natural testosterone production.
Related Products
